Structure Therapeutics recently reported positive topline Phase 2b and related ACCESS program data for its oral GLP-1 agonist aleniglipron in adults with obesity or overweight, showing clinically ...
AppLovin (APP) stock is rated Strong Buy with 32% upside. Learn about its AI-driven ad tech, growth, and premium valuation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results